Response : 'letter to the editor: emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa'
| Errataetall: |
CommentOn: Expert Opin Emerg Drugs. 2022 Dec;27(4):431-443. - PMID 36562395 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 27(2022), 4 vom: 26. Dez., Seite 449-450 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Martinez-Fernandez de la Camara, Cristina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
63231-63-0 |
|---|
| Anmerkungen: |
Date Completed 26.12.2022 Date Revised 14.02.2024 published: Print CommentOn: Expert Opin Emerg Drugs. 2022 Dec;27(4):431-443. - PMID 36562395 Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2022.2152212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350739110 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350739110 | ||
| 003 | DE-627 | ||
| 005 | 20240214232623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2022.2152212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM350739110 | ||
| 035 | |a (NLM)36562394 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Martinez-Fernandez de la Camara, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Response |b 'letter to the editor: emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa' |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2022 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Expert Opin Emerg Drugs. 2022 Dec;27(4):431-443. - PMID 36562395 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a AAV | |
| 650 | 4 | |a RP3 | |
| 650 | 4 | |a ciliopathy | |
| 650 | 4 | |a eye | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a glutamylation | |
| 650 | 7 | |a Proteins |2 NLM | |
| 650 | 7 | |a RNA |2 NLM | |
| 650 | 7 | |a 63231-63-0 |2 NLM | |
| 650 | 7 | |a Eye Proteins |2 NLM | |
| 650 | 7 | |a RPGR protein, human |2 NLM | |
| 700 | 1 | |a Cehajic-Kapetanovic, Jasmina |e verfasserin |4 aut | |
| 700 | 1 | |a MacLaren, Robert E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 27(2022), 4 vom: 26. Dez., Seite 449-450 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g number:4 |g day:26 |g month:12 |g pages:449-450 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2022.2152212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |e 4 |b 26 |c 12 |h 449-450 | ||